Advances in Protein Chemistry and Structural Biology

Erscheinungsjahr 2024
ISBN: 978-0-443-19342-2
Verlag: Elsevier Science & Technology

Buch, Englisch, Format (B × H): 151 mm x 229 mm, Gewicht: 450 g

Advances in Protein Chemistry and Structural Biology, Volume 138 covers reviews of methodology and research in all aspects of protein chemistry, including purification/expression, proteomics, modeling and structural determination and design. Chapters in this release include Proteomic Applications in Identifying Protein-Protein Interactions, Understanding functions of eEF1 translation elongation factors beyond translation. A proteomic approach, Proteomics provides insights into theranostic potential of extracellular vesicles, Towards a shareable functional analysis of the structural proteome, Functional unfoldomics, In-silico Network Pharmacology Study on Glycyrrhiza glabra: Analyzing the Immune-Boosting phytochemical properties of Siddha Medicinal Plant against COVID-19, and more.

Other chapters cover In silico Network Pharmacology Analysis and Molecular Docking Validation of Swasa Kudori for Screening Druggable Phytoconstituents of Asthma, Proteomics and Genomics Insights on Malignant Osteosarcoma, Application of functional proteomics in understanding RNA Virus-Mediated Infection, Biofilm proteome of Staphylococcus aureus: implications for therapeutic interventions to biofilm-associated infections, A computational pipeline elucidating functions of conserved hypothetical Trypanosoma cruzi proteins based on public proteomic data, Functional Proteomics based on Protein Microarray Technology for Biomedical Research, and an Analysis of endoglucanases production using proteomics and metatranscriptomics.

Autoren/Hrsg.

Weitere Mitwirkende

Donev, Rossen

Fachgebiete

• Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)
• Naturwissenschaften Chemie Organische Chemie

Über Autor(innen)

Donev, Rossen
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.